#China #Chengdu #Stapokibart #Keymed #R&D Progress

Keymed Biosciences' Promising Interim 2025 Results

In a significant announcement, Keymed Biosciences Inc. (02162.HK) has revealed robust interim results for the year 2025, a reflection of its accelerated commercialization strategies and proactive research and development (R&D) momentum. The Chengdu-based biotechnology company has reported a record revenue generation, underscored by its flagship product, Stapokibart, which operates as an IL-4Rα receptor antibody and is marketed under the brand name Kang Yue Da®.

Exceptional Financial Performance

Stapokibart has driven the company’s financial success by generating approximately 170 million RMB in net sales, demonstrating a strong market reception. Furthermore, to bolster its financial positioning and to facilitate continued growth, Keymed successfully raised around 864 million HKD through a strategic financing round. This funding will support the ongoing development and marketing efforts for an expanding product pipeline, ensuring that Keymed remains competitive in the rapidly evolving biopharmaceutical landscape.

Advancements in R&D Pipeline

Keymed's differentiated R&D pipeline showcases significant advancements that promise not only to enhance its product offerings but also to position the company as a leader in therapeutic innovations. Some key highlights include:

• - Stapokibart: Beyond its approved indications for adult atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps (CRSwNP), and seasonal allergic rhinitis (SAR), Keymed is progressing through phase III trials to evaluate the efficacy of Stapokibart in pediatric AD and nodular prurigo, thus expanding its clinical applications.

• - CMG901/AZD0901: This claudin 18.2 antibody-drug conjugate has seen a pivotal partnership in 2023, as AstraZeneca acquired exclusive global rights for its research, development, and commercialization. AstraZeneca is now advancing towards phase II/III clinical trials focusing on malignancies such as gastric, pancreatic, and biliary tract cancers.

• - CM512: A bispecific antibody targeting TSLP and IL-13 is under investigation in phase II trials for both atopic dermatitis and chronic rhinosinusitis, with patient recruitment currently underway.

Academic Influence and Publications

Keymed's academic contributions are marked by collaborations resulting in publications in prestigious journals, including The New England Journal of Medicine, Nature Medicine, and JAMA. These publications reinforce the validity of Stapokibart's clinical efficacy and illustrate the company’s vigorous research culture. Additionally, Stapokibart has been integrated into therapeutic guidelines in China, highlighting its recognized value within the medical community.

Strategic Outlook

Operating with strong cash reserves and an innovative product portfolio, Keymed is strategically positioned not only to cater to domestic markets but also to offer affordable and high-quality therapies internationally. The company remains focused on delivering groundbreaking solutions aimed at the healthcare challenges faced by patients both in China and globally.

As we delve deeper into 2025, Keymed Biosciences exemplifies what it means to blend robust financial performance with groundbreaking scientific development, setting a strong precedent in the biotechnology sector. The upcoming months will indeed be critical as the firm pushes forward with its ambitious plans for growth and therapeutic reach, making a substantial impact in the biopharmaceutical industry.